Perigon Wealth Management LLC maintained its stake in Allergan PLC. (NYSE:AGN) during the first quarter, Holdings Channel reports. The firm owned 15,240 shares of the company’s stock at the end of the first quarter. Perigon Wealth Management LLC’s holdings in Allergan PLC. were worth $3,641,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of AGN. Crestwood Advisors Group LLC purchased a new stake in shares of Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. purchased a new stake in shares of Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp raised its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC raised its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the last quarter. Finally, JNBA Financial Advisors raised its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. 84.77% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (AGN) traded up 0.31% during mid-day trading on Friday, reaching $232.92. The company’s stock had a trading volume of 843,449 shares. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company’s 50-day moving average price is $246.34 and its 200 day moving average price is $238.00. The firm has a market capitalization of $78.07 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 EPS. On average, equities analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.21%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

WARNING: “Perigon Wealth Management LLC Has $3,641,000 Position in Allergan PLC. (AGN)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/11/perigon-wealth-management-llc-has-3641000-position-in-allergan-plc-agn.html.

Several brokerages recently commented on AGN. UBS AG reaffirmed an “outperform” rating and issued a $275.00 price objective on shares of Allergan PLC. in a report on Wednesday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $278.00 price objective (up previously from $273.00) on shares of Allergan PLC. in a report on Wednesday. BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday. Finally, Credit Suisse Group set a $288.00 target price on Allergan PLC. and gave the company a “buy” rating in a research report on Saturday, August 5th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Allergan PLC. currently has an average rating of “Buy” and an average target price of $274.49.

In related news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is owned by insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.